[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537168":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":49,"collaborators":24,"id":51,"slug":24,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":24,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Cosmetique Active International","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: holistic approach","EXPERIMENTAL","adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion\u002Fexclusion criteria including a Tolak® treatment planned before study start",[13],"Other: Group A: holistic approach",{"label":15,"type":16,"description":11,"interventionNames":17},"Group B: Tolak® Standard of use","ACTIVE_COMPARATOR",[18],"Other: Group B: Tolak® Standard of use",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"OTHER","2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"4-week Tolak® alone treatment (once daily in the evening)",[15],[29],{"name":30,"affiliation":31,"role":32},"Thomas Dirschka","CentroDerm GmbH","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","+49 2 02 \u002F 629337-32","s.weber@centroderm.de",[39],{"facility":31,"status":40,"city":41,"state":24,"zip":24,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":24},"RECRUITING","Wuppertal","Germany",{"type":44,"coordinates":45},"Point",[46,47],7.14816,51.25627,{"lat":47,"lon":46},{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100537168",false,"NCT06274320","Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment","Investigation of the Effect of a 2 Weeks Lipikar Urea 30% Application Preceding a Planned Topical 5-FU 4% Actinic Keratoses Treatment on Efficacy of 5-FU 4%","Inclusion Criteria:\n\n* diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp\n* planned treatment of actinic keratoses of the scalp with Tolak®\n* Olsen grade I or II\n\nExclusion Criteria:\n\n* known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%\n* treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)\n* suspected invasive squamous cell cancer in the treatment area\n* chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil",true,"ALL","18 Years",{"count":61,"type":62},100,"ESTIMATED","INTERVENTIONAL",[65],"NA","This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion\u002Fexclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.",[68],"Actinic Keratoses",[70,71,72],"actinic keratoses","Lipikar Urea 30%","Olsen grade","2024-06-14",{"date":75,"type":76},"2024-06-18","ACTUAL",{"date":78,"type":76},"2024-04-05",{"date":80,"type":62},"2025-06",{"name":5,"class":6},1]